Stoke Therapeutics ((STOK)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The EMPEROR study, officially titled ‘A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome,’ aims to assess the efficacy, safety, and tolerability of zorevunersen in treating Dravet syndrome. This study is significant as it explores a potential new treatment for a challenging condition.
Zorevunersen, an antisense oligonucleotide, is designed to increase the expression of the Nav1.1 protein by upregulating the SCN1A gene’s nonmutant copy. This RNA-based approach aims to restore physiological Nav1.1 levels in patients with Dravet syndrome, potentially modifying the disease.
The study employs a randomized, parallel-group design with quadruple masking, focusing on treatment as the primary purpose. Participants are allocated to either the zorevunersen or sham comparator group, with the primary endpoint being the change in major motor seizure frequency.
The study began on June 4, 2025, with the last update submitted on July 14, 2025. These dates are crucial as they mark the study’s progression and the latest information available to the public.
The update on this study could positively influence Stoke Therapeutics’ stock performance by boosting investor confidence in the company’s innovative approach. The study’s progress is closely monitored by investors, especially given the competitive landscape in the treatment of neurological disorders.
The EMPEROR study is ongoing, with further details available on the ClinicalTrials portal.